On January 8, 2020 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that Amit D. Munshi, the Company’s President and Chief Executive Officer, will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, at 1:00 PM ET (10:00 AM PT) (Press release, Arena Pharmaceuticals, JAN 8, 2020, View Source [SID1234552879]). The conference will take place January 13-16, 2020, at the Westin St. Francis Hotel in San Francisco.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be posted under the investor relations section of Arena’s website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event.

On January 8, 2020 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9, 2020 at 8:45am ET in New York (Press release, BioMarin, JAN 8, 2020, View Source [SID1234552878]). To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 8, 2020 ViaCyte, Inc., a privately-held regenerative medicine company, reported that ViaCyte’s President and CEO Paul Laikind, Ph.D. will present at Biotech Showcase 2020, to be held January 13 to 15 at the Hilton San Francisco Union Square (Press release, ViaCyte, JAN 8, 2020, View Source [SID1234552877]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Dr. Laikind will discuss ViaCyte’s leadership in discovering and developing novel cell replacement therapies to treat human diseases. The company has two product candidates, PEC-Direct and PEC-Encap (also known as VC-01), in clinical trials. Both have the potential to transform the way type 1 diabetes is managed to the extent of providing a functional cure for the disease. With CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 pluripotent stem cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2, as well as other potential indications. The Company’s leadership is reflected in its robust intellectual property portfolio, which includes hundreds of issued patents and pending applications worldwide.

"ViaCyte has made significant clinical progress advancing a stem cell-derived islet replacement therapy for type 1 diabetes, including the first demonstration of human C-peptide production (a biomarker for insulin production) in patients receiving the PEC-Direct product candidate. These patients were unable to produce detectable levels of C-Peptide before treatment," said Dr. Laikind. "With the significant clinical progress we made last year, we expect that this year we can accelerate our mission to deliver transformative therapies for insulin-requiring diabetes."

Dr. Laikind will be presenting at Biotech Showcase as follows:

Date: Monday, January 13, 2020
Time: 11:15 am PST
Room: Franciscan C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

On January 8, 2020 Cellect Biotechnology Ltd. (Nasdaq: APOP) ("Cellect" or the "Company"), a developer of innovative technology which enables the functional selection of stem cells, reported it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,000,000 American Depositary Shares ("ADSs"), each representing 100 of the Company’s ordinary shares, at an offering price of $3.00 per ADS, pursuant to a registered direct offering (Press release, Cellect Biotechnology, JAN 8, 2020, View Source [SID1234552876]). The gross proceeds of the offering will be approximately $3,000,000 before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about January 10, 2020, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

This offering was made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-219614) previously filed with the U.S. Securities and Exchange Commission (the "SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A prospectus supplement relating to the shares of common stock will be filed by Cellect with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, New York 10022 or by email at [email protected].

On January 8, 2020 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA;OTCQB: MDNAF), a clinical stage immuno-oncology company, reported that it has received $1,345,871 from the early exercise of previously issued warrants (Press release, Medicenna Therapeutics, JAN 8, 2020, View Source [SID1234552875]). A total of 855,621 warrants were exercised, with exercise prices ranging from $1.20-$2.00. The proceeds of the warrant exercises will be used towards the development of Medicenna’s long-acting IL-2 superkine (MDNA19) and for general and working capital purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This early exercise of warrants is a clear indicator of the confidence that investors have in Medicenna and our short and long-term opportunities," says Fahar Merchant, President and Chief Executive Officer of Medicenna. "Combined with our recent oversubscribed financing, these funds provide us with a robust balance sheet that will see us through important upcoming milestones, including the completion of a full MDNA55 data set and subsequent meeting with the FDA, the ongoing advancement of our best-in-class IL-2 asset MDNA19 and our ongoing operations into 2021."

The exercises consist of 274,000 warrants priced at $1.20 and expiring December 21, 2023, 526,621 warrants priced at $1.75 and expiring October 17, 2022, 5,000 warrants priced at $1.20 and expiring December 21, 2020, 15,000 warrants priced at $1.30 and expiring October 17, 2021 and 35,000 warrants priced at $2.00 and expiring April 5, 2021. The number of issued and outstanding common shares following the exercises is 34,991,097.